Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

E. Anders Kolb, Richard Gorlick, Peter J. Houghton, Christopher L. Morton, Richard Lock, Hernan Carol, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Background. SCH 717454 (19D12) is a fully human antibody directed against the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies. The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures. SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection. Results. SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel. In vivo, SCH 717454 significantly increased event-free survival in 20 of 35 (57%) solid tumor xenograft models with tumor regressions in one Ewing sarcoma model (complete response) and 2 osteosarcoma models (maintained complete responses). LJsing the time to event activity measure, SCH 717454 had intermediate (n = 9) or high (n = 1) activity against 31 evaluable solid tumor xenografts, including xenografts from the rhabdoid tumor, Ewing, rhabdomyosarcoma, glioblastoma, neuroblastoma, and osteosarcoma panels. SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel. Conclusions. SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels. Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated.

Original languageEnglish (US)
Pages (from-to)1190-1197
Number of pages8
JournalPediatric Blood and Cancer
Volume50
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

IGF Type 1 Receptor
Monoclonal Antibodies
Pediatrics
Heterografts
Osteosarcoma
Neoplasms
Rhabdoid Tumor
Somatomedin Receptors
SCH 717454
Ewing's Sarcoma
Rhabdomyosarcoma
Glioblastoma
Growth
Intraperitoneal Injections
Neuroblastoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antineoplastic Agents
Disease-Free Survival
Phenotype
Cell Line

Keywords

  • Developmental therapeutics
  • IGF-1R
  • Preclinical testing
  • SCH 717454

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Anders Kolb, E., Gorlick, R., Houghton, P. J., Morton, C. L., Lock, R., Carol, H., ... Smith, M. A. (2008). Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50(6), 1190-1197. https://doi.org/10.1002/pbc.21450

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. / Anders Kolb, E.; Gorlick, Richard; Houghton, Peter J.; Morton, Christopher L.; Lock, Richard; Carol, Hernan; Patrick Reynolds, C.; Maris, John M.; Keir, Stephen T.; Billups, Catherine A.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 50, No. 6, 06.2008, p. 1190-1197.

Research output: Contribution to journalArticle

Anders Kolb, E, Gorlick, R, Houghton, PJ, Morton, CL, Lock, R, Carol, H, Patrick Reynolds, C, Maris, JM, Keir, ST, Billups, CA & Smith, MA 2008, 'Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 50, no. 6, pp. 1190-1197. https://doi.org/10.1002/pbc.21450
Anders Kolb, E. ; Gorlick, Richard ; Houghton, Peter J. ; Morton, Christopher L. ; Lock, Richard ; Carol, Hernan ; Patrick Reynolds, C. ; Maris, John M. ; Keir, Stephen T. ; Billups, Catherine A. ; Smith, Malcolm A. / Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2008 ; Vol. 50, No. 6. pp. 1190-1197.
@article{7d64973bcc4e497da2d5aca4283a9308,
title = "Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program",
abstract = "Background. SCH 717454 (19D12) is a fully human antibody directed against the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies. The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures. SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection. Results. SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel. In vivo, SCH 717454 significantly increased event-free survival in 20 of 35 (57{\%}) solid tumor xenograft models with tumor regressions in one Ewing sarcoma model (complete response) and 2 osteosarcoma models (maintained complete responses). LJsing the time to event activity measure, SCH 717454 had intermediate (n = 9) or high (n = 1) activity against 31 evaluable solid tumor xenografts, including xenografts from the rhabdoid tumor, Ewing, rhabdomyosarcoma, glioblastoma, neuroblastoma, and osteosarcoma panels. SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel. Conclusions. SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels. Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated.",
keywords = "Developmental therapeutics, IGF-1R, Preclinical testing, SCH 717454",
author = "{Anders Kolb}, E. and Richard Gorlick and Houghton, {Peter J.} and Morton, {Christopher L.} and Richard Lock and Hernan Carol and {Patrick Reynolds}, C. and Maris, {John M.} and Keir, {Stephen T.} and Billups, {Catherine A.} and Smith, {Malcolm A.}",
year = "2008",
month = "6",
doi = "10.1002/pbc.21450",
language = "English (US)",
volume = "50",
pages = "1190--1197",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

AU - Anders Kolb, E.

AU - Gorlick, Richard

AU - Houghton, Peter J.

AU - Morton, Christopher L.

AU - Lock, Richard

AU - Carol, Hernan

AU - Patrick Reynolds, C.

AU - Maris, John M.

AU - Keir, Stephen T.

AU - Billups, Catherine A.

AU - Smith, Malcolm A.

PY - 2008/6

Y1 - 2008/6

N2 - Background. SCH 717454 (19D12) is a fully human antibody directed against the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies. The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures. SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection. Results. SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel. In vivo, SCH 717454 significantly increased event-free survival in 20 of 35 (57%) solid tumor xenograft models with tumor regressions in one Ewing sarcoma model (complete response) and 2 osteosarcoma models (maintained complete responses). LJsing the time to event activity measure, SCH 717454 had intermediate (n = 9) or high (n = 1) activity against 31 evaluable solid tumor xenografts, including xenografts from the rhabdoid tumor, Ewing, rhabdomyosarcoma, glioblastoma, neuroblastoma, and osteosarcoma panels. SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel. Conclusions. SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels. Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated.

AB - Background. SCH 717454 (19D12) is a fully human antibody directed against the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies. The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures. SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection. Results. SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel. In vivo, SCH 717454 significantly increased event-free survival in 20 of 35 (57%) solid tumor xenograft models with tumor regressions in one Ewing sarcoma model (complete response) and 2 osteosarcoma models (maintained complete responses). LJsing the time to event activity measure, SCH 717454 had intermediate (n = 9) or high (n = 1) activity against 31 evaluable solid tumor xenografts, including xenografts from the rhabdoid tumor, Ewing, rhabdomyosarcoma, glioblastoma, neuroblastoma, and osteosarcoma panels. SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel. Conclusions. SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels. Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated.

KW - Developmental therapeutics

KW - IGF-1R

KW - Preclinical testing

KW - SCH 717454

UR - http://www.scopus.com/inward/record.url?scp=42349083307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42349083307&partnerID=8YFLogxK

U2 - 10.1002/pbc.21450

DO - 10.1002/pbc.21450

M3 - Article

C2 - 18260118

AN - SCOPUS:42349083307

VL - 50

SP - 1190

EP - 1197

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -